Movement Industries Corp (MVNT)

[Kronborg]

From last letter to shareholders.

Despite much protest and resistance, the White House means to enforce meaningful use standards and maintain its focus on the reduction of Adverse Drug Events which are costly in both financial and human terms. The following is a review of some of the key factors that will be driving our business in the next decade.

It has been estimated that some 40% of hospital expenses are the result of medical errors, adverse drug interactions, readmission due to incomplete procedures, readmission due to avoidable complication, and neglect or lack of home care, all of which can be significantly reduced by using a smart clinical system like ours.
The potential of home care can only be realized if clinical vital signs measured by patients at home are properly transmitted to a clinical system.
Most clinical vital signs, if transmitted, need to be processed by an automated data repository that can provide real alerts and interpretation.
Most patients do not use their medications as intended and the resulting inefficiency contributes to the cost factor. Few systems exist that can intervene in a non-invasive manner. VisualMED is participating in the creation of a network for instant collection and interpretation of home-based vital signs.
The real number of Americans who die each year from Adverse Drug Events is estimated to be even higher than the current estimate of 300,000. The Institute of Medicine (IOM) has been advocating the adoption of smart computerized order entry (CPOE) as a tool that has been proven to sharply reduce the occurrence of ADEs.
On a larger scale, medical literature suggests that one patient in six is victim of an adverse drug event (ADE) or other potentially lethal error.
Iatrogenic errors have been steadily climbing and are now a major cause of mortality.
A great deal of diagnostic information generated by smart machines and automated labs ends up being lost or used wrongfully because physicians are not connected.
Clinical trials are increasingly under pressure to adopt electronic tools and data analysis in order to lower cost and meet new standards from the FDA.
Scientific research continues to grow exponentially and our new applications for the lab provide an edge in this very competitive world.

http://www.visualhealthcarecorp.com/publication-july-19-2011.html


Kronborg